ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0949

Shen-Qi-Yan-Shen Formula Attenuates Diabetic Renal Lipid Deposition by Down-Regulating Proteoglycan Expression

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Li, Ying, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China
  • Xiong, Weijian, Chongqing Traditional Chinese Medicine Hospital, Chongqing, China
Background

Renal lipid deposition is a crucial factor in the pathophysiology of diabetic nephropathy (DN). Proteoglycan (PG) is an important component of the extracellular matrix. Shen-Qi-Yan-Shen Formula (SQYSF) is a clinical empirical formula in treating DN. In this study, db/db mice are used to explore the potential mechanism of SQYSF by down-regulating PG expression.

Methods

We divide the mice into db/m normal control group, db/db model group, SQYSF treated group, captopril treated group, and SQYSF + captopril treated group. The groups of mice are given continuous administration of saline, SQYSF, captopril or SQYSF + captopril for 12 weeks, respectively.

Results

We have revealed that treating db/db mice with SQYSF protects them against renal injury. Our finding is supported by lower blood urea nitrogen and serum creatinine and less urinary albumin in the treated mice compared with the saline-treated db/db controls . Mice treated with SQYSF have significantly reduced protein levels of fasting blood glucose (FBG), HbA1c, TG, LDL-c and HDL-c . SQYSF markedly down-regulates protein expression of proteoglycan (PG), apoB and LDL- receptor in the db/db mice. In addition, captopril exhibits a partial inhibitory effect on PG and other proteins, which can be enhanced by SQYSF .

Conclusion

SQYSF may protect db/db mice by relieving lipid deposition through the down-regulation of PG. These encouraging results corroborate SQYSF’s potential of becoming a novel therapeutic strategy for diabetic nephropathy.

Funding

  • Government Support - Non-U.S.